News
-
09.02.2010
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C - -
04.02.2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
| Licensing-out |
|
We would typically partner our products at human proof of concept stage or later on. It is crucial that our products are commercialised by the appropriate commercial partner for the best possible fit. We make sure that the inventor and the marketing company are fairly remunerated for their work. Financial scenarios are analysed, commercial terms are negotiated, the future envisioned and discussed, legal contracts put in place and business alliance management implemented to ensure the product is optimally exploited. |



